Poly Medicure Limited (IN:POLYMED)
:POLYMED
Want to see IN:POLYMED full AI Analyst Report?
Top Page
Poly Medicure Limited
(POLYMED)
Select Model
Select Model
Rating:67Neutral
Price Target:
₹1,292.00
▼(-25.04% Downside)
Action:DowngradedDate:02/07/26
The score is supported primarily by strong underlying financial performance (growth, profitability, and low leverage), but is held back by a pronounced technical downtrend and an expensive valuation with a minimal dividend yield.
Positive Factors
Revenue and Margin Trends
Consistent revenue expansion combined with strong gross and improving net margins indicates durable demand and effective cost control. This underpins sustainable internal cash generation, supports reinvestment for growth, and enhances the firm's ability to absorb cyclical pressures over months to years.
Negative Factors
Negative Free Cash Flow from CapEx
Sustained negative free cash flow driven by heavy capex reduces free liquidity and may force reliance on external funding or slower payout growth. If new investments take time to mature, cash strain could limit optionality and constrain returns to shareholders over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Margin Trends
Consistent revenue expansion combined with strong gross and improving net margins indicates durable demand and effective cost control. This underpins sustainable internal cash generation, supports reinvestment for growth, and enhances the firm's ability to absorb cyclical pressures over months to years.
Read all positive factors
Poly Medicure Limited (POLYMED) vs. iShares MSCI India ETF (INDA)
Market Cap
₹143.38B
Dividend Yield0.19%
Average Volume (3M)8.86K
Price to Earnings (P/E)63.3
Beta (1Y)0.90
Revenue Growth10.86%
EPS Growth6.36%
CountryIN
Employees6,300
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)7.85
Shares Outstanding101,359,490
10 Day Avg. Volume7,511
30 Day Avg. Volume8,860
Financial Highlights & Ratios
PEG Ratio2.36
Price to Book (P/B)7.72
Price to Sales (P/S)12.79
P/FCF Ratio-235.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)39.23
Revenue Forecast (FY)₹22.62B
Poly Medicure Limited Business Overview & Revenue Model
Company Description
Poly Medicure Limited manufactures and sells medical devices. It offers infusion devices, such as I.V. cannulas, mid line catheters, arterial cannula, three way stop cocks, I.V. infusion sets, manifolds, safety winged infusion sets, T-type extensi...
How the Company Makes Money
Poly Medicure makes money primarily by selling single-use (disposable) medical devices and consumables to healthcare providers and to distribution/export channels. Revenue is generated across multiple product categories such as infusion-related di...
Poly Medicure Limited Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
80
Positive
Cash Flow
75
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.12B | 16.70B | 13.76B | 11.15B | 9.23B | 7.86B |
| Gross Profit | 10.53B | 11.11B | 8.89B | 7.06B | 5.72B | 5.23B |
| EBITDA | 4.82B | 4.52B | 3.58B | 2.68B | 2.12B | 2.13B |
| Net Income | 3.62B | 3.39B | 2.58B | 1.79B | 1.47B | 1.36B |
Balance Sheet | ||||||
| Total Assets | 35.87B | 31.92B | 18.59B | 15.77B | 13.77B | 12.24B |
| Cash, Cash Equivalents and Short-Term Investments | 11.06B | 12.08B | 2.86B | 3.01B | 3.52B | 3.74B |
| Total Debt | 2.40B | 1.80B | 1.74B | 1.49B | 1.27B | 1.37B |
| Total Liabilities | 6.55B | 4.27B | 3.89B | 3.36B | 2.89B | 2.58B |
| Stockholders Equity | 29.18B | 27.66B | 14.70B | 12.42B | 10.87B | 9.66B |
Cash Flow | ||||||
| Free Cash Flow | -658.89M | -906.06M | -109.34M | -484.49M | -321.05M | 236.01M |
| Operating Cash Flow | 914.43M | 2.40B | 2.66B | 1.91B | 1.23B | 1.19B |
| Investing Cash Flow | -1.23B | -11.94B | -2.41B | -1.79B | -853.32M | -4.36B |
| Financing Cash Flow | 492.71M | 9.51B | -201.53M | -125.05M | -353.38M | 3.17B |
Poly Medicure Limited Technical Analysis
Neutral
1723.55
Price Trends
1343.87
Positive
1562.96
Negative
1785.26
Negative
Market Momentum
40.95
Negative
61.11
Neutral
89.08
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:POLYMED, the sentiment is Neutral. The current price of 1723.55 is above the 20-day moving average (MA) of 1338.64, above the 50-day MA of 1343.87, and below the 200-day MA of 1785.26, indicating a neutral trend. The MACD of 40.95 indicates Negative momentum. The RSI at 61.11 is Neutral, neither overbought nor oversold. The STOCH value of 89.08 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:POLYMED.
Poly Medicure Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ₹190.67B | 51.42 | ― | 0.47% | 12.37% | 30.97% | |
67 Neutral | ₹143.38B | 63.35 | ― | 0.19% | 10.86% | 6.36% | |
63 Neutral | ₹418.95B | 35.44 | ― | 2.16% | 2.59% | 18.83% | |
61 Neutral | ₹282.43B | 27.13 | ― | 1.07% | 6.70% | 20.25% | |
57 Neutral | ₹147.64B | 31.27 | ― | 1.28% | 13.20% | 4.00% | |
53 Neutral | ₹648.51B | 35.61 | ― | 0.24% | 25.44% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:POLYMED
Poly Medicure Limited
1,511.25
-1,067.82
-41.40%
IN:APLLTD
Alembic Pharmaceuticals Limited
759.85
-109.76
-12.62%
IN:ERIS
Eris Lifesciences Ltd
1,324.05
-140.50
-9.59%
IN:GLAND
Gland Pharma Ltd.
1,761.75
361.79
25.84%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,410.60
-456.53
-15.92%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,404.95
1,024.14
74.17%
Poly Medicure Limited Corporate Events
Poly Medicure Schedules One-on-One Virtual Meet With Investors on 19 March 2026
Mar 12, 2026
Poly Medicure Limited has scheduled a virtual one-on-one meeting with analysts and investors, organized by Avendus Spark, on 19 March 2026 at 5:00 p.m. The company stated that the engagement falls under regulatory disclosure requirements and empha...
Poly Medicure Schedules One-on-One Investor Meet With Ellerston Capital
Mar 10, 2026
Poly Medicure Limited has scheduled a one-on-one virtual meeting with Ellerston Capital on March 18, 2026, as part of its regular investor and analyst engagement under securities listing regulations. The company emphasized that no unpublished pric...
Poly Medicure to Engage Investors at Investec India Promoter & Founder Conference 2026
Mar 3, 2026
Poly Medicure Limited has announced that its officials will participate in the Investec India Promoter Founder Conference 2026, engaging with analysts and institutional investors through one-on-one and group meetings in Mumbai on 9 and 10 March 2...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.